✦ LIBER ✦

Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial

✍ Scribed by Takaki Yoshikawa MD, PhD, Kazuaki Tanabe MD, Kazuhiro Nishikawa MD, Yuichi Ito MD, Takanori Matsui MD, Yutaka Kimura MD, PhD, Naoki Hirabayashi MD, Shoki Mikata MD, Makoto Iwahashi MD, Ryoji Fukushima MD, Nobuhiro Takiguchi MD, Isao Miyashiro MD, Satoshi Morita PhD, Yumi Miyashita, Aakira Tsuburaya MD, Junichi Sakamoto MD…show all 16hide

Book ID: 120965379
Publisher: Springer
Year: 2013
Tongue: English
Weight: 214 KB
Volume: 21
Category: Article
ISSN: 1068-9265
DOI: 10.1245/s10434-013-3055-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neoadjuvant Chemotherapy Followed by Lat

Neoadjuvant Chemotherapy Followed by Late-Course Accelerated Hyperfractionated Radiation Therapy for Locally Advanced Non–Small-Cell Lung Cancer: Long-Term Results of a Phase I/II Clinical Trial

✍ Ming Chen; Yuan-Yuan Chen; Yong Bao; Chao-Gui Xian; Guo-Zhen Liu; Li Zhang; Guan 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 496 KB

P301 Addition of pertuzumab (P) to trast

P301 Addition of pertuzumab (P) to trastuzumab (H)-based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: Result of a randomised phase II study (NEOSPHERE)

✍ L. Gianni; T. Pienkowski; Y.-H. Im; L. Roman; L.-M. Tseng; M.-C. Liu; A. Lluch-H 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 37 KB

6500 ORAL Randomized phase II trial usin

6500 ORAL Randomized phase II trial using concomitant chemoradiation plus induction (I) or consolidation (C) chemotherapy (CT) for unresectable stage III non-small cell lung cancer (NSCLC) patients (pts). Mature results of the SLCG 0008 study

✍ Garrido, P.; Massuti, B.; Jimenez, A.; Samper, P.; Mesia, C.; Rodriguez, N.; Lia 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 78 KB

A phase II trial of individualized respo

A phase II trial of individualized response-based induction chemotherapy (IC) of mitomycin-C, vindesine, cisplatin (MVP) followed by thoracic radiotherapy (TRT) with daily low-dose carboplatin (CBDCA) for the treatment of unresectable stage III non-small-cell lung cancer (NSCLC)

✍ Shinbo, T; Makino, M; Tsukada, H; Yokoyama, A; Saitou, M; Kurita, Y 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 230 KB

O-040 Randomized phase III trial for sta

O-040 Randomized phase III trial for stage III unresectable nonsmall cell lung (NSCLC) cancer: Induction Chemotherapy (ICT) [vinorelbine (Vr)-cisplatine (P)] followed by conventional radiation (RT) without (arm A) or with daily carboplatin (Cb) (arm B). Final results. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT

✍ Douillard, J.; Gervais, R.; Quoix, E.; Le Chevalier, T.; Le Groumellec, A.; Lema 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 142 KB